Cargando…
Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication
We previously isolated an HSV-1 mutant, KOS-NA, that contains two non-synonymous mutations in UL39. One of the mutations, resulting in an R950H amino acid substitution in ICP6, renders KOS-NA severely neuro-attenuated and significantly reduces HSV-1 latency. Vaccination of mice with KOS-NA prior to...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144315/ https://www.ncbi.nlm.nih.gov/pubmed/35632611 http://dx.doi.org/10.3390/v14050869 |
_version_ | 1784716018593038336 |
---|---|
author | Wang, Hong Davido, David J. Mostafa, Heba H. Morrison, Lynda A. |
author_facet | Wang, Hong Davido, David J. Mostafa, Heba H. Morrison, Lynda A. |
author_sort | Wang, Hong |
collection | PubMed |
description | We previously isolated an HSV-1 mutant, KOS-NA, that contains two non-synonymous mutations in UL39. One of the mutations, resulting in an R950H amino acid substitution in ICP6, renders KOS-NA severely neuro-attenuated and significantly reduces HSV-1 latency. Vaccination of mice with KOS-NA prior to corneal challenge provides significant protection against HSV-1-mediated eye diseases even at a very low immunizing dose, indicating its utility as a vaccine scaffold. Because KOS-NA contains a neuro-attenuating mutation in a single gene, we sought to improve its safety by deleting a portion of the UL29 gene whose protein product, ICP8, is essential for viral DNA replication. Whereas KOS-NA reduced replication of HSV-1 challenge virus in the corneal epithelium and protected mice against blepharitis and keratitis induced by the challenge virus, KOS-NA/8- and an ICP8- virus were significantly less efficacious except at higher doses. Our results suggest that the capacity to replicate, even at significantly reduced levels compared with wild-type HSV-1, may be an important feature of an effective vaccine. Means to improve safety of attenuated viruses as vaccines without compromising efficacy should be sought. |
format | Online Article Text |
id | pubmed-9144315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91443152022-05-29 Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication Wang, Hong Davido, David J. Mostafa, Heba H. Morrison, Lynda A. Viruses Article We previously isolated an HSV-1 mutant, KOS-NA, that contains two non-synonymous mutations in UL39. One of the mutations, resulting in an R950H amino acid substitution in ICP6, renders KOS-NA severely neuro-attenuated and significantly reduces HSV-1 latency. Vaccination of mice with KOS-NA prior to corneal challenge provides significant protection against HSV-1-mediated eye diseases even at a very low immunizing dose, indicating its utility as a vaccine scaffold. Because KOS-NA contains a neuro-attenuating mutation in a single gene, we sought to improve its safety by deleting a portion of the UL29 gene whose protein product, ICP8, is essential for viral DNA replication. Whereas KOS-NA reduced replication of HSV-1 challenge virus in the corneal epithelium and protected mice against blepharitis and keratitis induced by the challenge virus, KOS-NA/8- and an ICP8- virus were significantly less efficacious except at higher doses. Our results suggest that the capacity to replicate, even at significantly reduced levels compared with wild-type HSV-1, may be an important feature of an effective vaccine. Means to improve safety of attenuated viruses as vaccines without compromising efficacy should be sought. MDPI 2022-04-22 /pmc/articles/PMC9144315/ /pubmed/35632611 http://dx.doi.org/10.3390/v14050869 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wang, Hong Davido, David J. Mostafa, Heba H. Morrison, Lynda A. Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication |
title | Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication |
title_full | Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication |
title_fullStr | Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication |
title_full_unstemmed | Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication |
title_short | Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication |
title_sort | efficacy of an hsv-1 neuro-attenuated vaccine in mice is reduced by preventing viral dna replication |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144315/ https://www.ncbi.nlm.nih.gov/pubmed/35632611 http://dx.doi.org/10.3390/v14050869 |
work_keys_str_mv | AT wanghong efficacyofanhsv1neuroattenuatedvaccineinmiceisreducedbypreventingviraldnareplication AT davidodavidj efficacyofanhsv1neuroattenuatedvaccineinmiceisreducedbypreventingviraldnareplication AT mostafahebah efficacyofanhsv1neuroattenuatedvaccineinmiceisreducedbypreventingviraldnareplication AT morrisonlyndaa efficacyofanhsv1neuroattenuatedvaccineinmiceisreducedbypreventingviraldnareplication |